The Cost-Effectiveness of Sildenafil
- 20 June 2000
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 132 (12), 933-937
- https://doi.org/10.7326/0003-4819-132-12-200006200-00002
Abstract
Coverage of sildenafil by health insurance plans is a contentious issue. To evaluate the cost-effectiveness of sildenafil treatment for erectile dysfunction. A Markov decision model to estimate the incremental cost-effectiveness of sildenafil compared with no drug therapy. Values for the efficacy and safety of sildenafil and quality-of-life utilities were obtained from the published medical literature. Base-case values were chosen to bias against sildenafil use. Men 60 years of age with erectile dysfunction. Lifetime. Societal and third-party payer. Sildenafil or no treatment in identical hypothetical cohorts. Cost per quality-adjusted life-year (QALY) gained. The cost per QALY gained for sildenafil treatment compared with no therapy was $11 290 from the societal perspective and $11 230 from the third-party payer perspective. From the societal perspective, the cost per QALY gained associated with sildenafil was less than $50 000 if treatment-related morbidity was less than 0.8% per year, mortality was less than 0.55% per year, treatment was successful in more than 40.2% of patients, or sildenafil cost less than $244 per month. The results were sensitive to variation of erectile dysfunction utilities, but cost per QALY gained was less than $50 000 if successful treatment increased utility values by 0.05 or more on a scale of 0 (death) to 1 (perfect health). In an analysis biased against use of sildenafil, the cost-effectiveness of sildenafil treatment compared favorably with that of accepted therapies for other medical conditions.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologiesUrology, 1999
- Sildenafil citrate (viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjectsUrology, 1999
- Sildenafil (Viagra) is used as a recreational drug in EnglandBMJ, 1999
- Viagra: a botched test case for rationingBMJ, 1999
- Use of Sildenafil (Viagra) in Patients With Cardiovascular DiseaseCirculation, 1999
- Viagra is licensed in Europe but rationed in BritainBMJ, 1998
- Acute myocardial infarction associated with sildenafilThe Lancet, 1998
- Oral Sildenafil in the Treatment of Erectile DysfunctionNew England Journal of Medicine, 1998
- Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile DysfunctionNew England Journal of Medicine, 1996
- Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging StudyJournal of Urology, 1994